The PROMISE Initiative: Accelerating Cancer Innovation
October 13, 2026 @ 09:00 – 17:00 CEST
Cancer encompasses more than 200 distinct diagnoses, each with widely varying prognoses, from highly treatable to very poor outcomes. Advances in molecular analysis hold great promise for diagnostics and therapies, enabling more precise and effective approaches tailored to individual patients with cancer. Sweden has excellent cancer registries and biobanks of the highest quality,and there is now a need to join forces to exploit our unique advantages to the benefit of cancer patients. SciLifeLab platforms support the generation and analysis of data in both genomics and other omics technologies.
The goal of the conference is to expand the PROMISECancer consortium, promote its efforts, and continue building the Swedish cancer community. PROMISE Cancer is a part of PROMISE: Precision Omics Initiative Sweden, which is a national initiative using whole-genome sequencing and multiomics to understand common diseases, rare diseases, and cancer.
This conference will focus on the PROMISE Cancer effort led by Swedish scientists representing Stockholm, Uppsala, Umeå, Linköping, Lund, and Gothenburg as well as SciLifeLab.
Here, we aim to have high-quality national and international speakers from the many areas needed for improved precisionomics. 1: Cancer genomics, 2: Single cell and spatial transcriptomics and multiomics, 3: Germline cancer risk and liquid biopsies, and 4: Functional precision cancer medicine. An additional purpose is to share updates on the progress made within PROMISE Cancer and to encourage broader participation of Swedish cancer researchers. While the current work is primarily focused on preclinical and translational research, the overarching goal is to translate these findings into clinical practice through collaboration with Genomic Medicine Sweden (GMS).
Google Calendar 
